BMP4 and glioma: Findings demonstrate that despite MSC1 showing anti‐glioma benefits in vitro, engineering of MSC1 with BMP4 did not substantially improve survival against its counterpart suggesting that the technical capability of a donor is necessary, but not sufficient, to ensure therapeutic potency.